Category Archives: Hepatitis C

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine, Affordable generic versions from China could save millions of people’s lives

Source: Medecins Sans Frontieres |June 19, 2018 The international medical humanitarian organisation Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation … Continue reading

Posted in Hepatitis C, Patent, Patent Enforcement | Leave a comment

NGO alleges ‘stock-out’ of Hepatitis C drugs at city hospital

Source: PTI | Published: India Today New Delhi: An NGO today alleged that at a Delhi government hospital had run out of Hepatitis C medicines, causing inconvenience to patients. “After a prolonged struggle, DNP+ and patients with HCV (Hepatitis C … Continue reading

Posted in Hepatitis C, Uncategorized | Leave a comment

Focusing on Neglected Patients

Source: Lasker Foundation | April 25, 2018 Rachel Cohen is the regional executive director of the Drugs for Neglected Diseases initiative (DNDi), a nonprofit drug research and development organization focused on diseases such as leishmaniasis and sleeping sickness. Previously, she worked … Continue reading

Posted in Hepatitis C, HIV/Aids, Neglected Diseases, Uncategorized | Leave a comment

Patent on Hep C drug rejected in Ukraine: Price of sofosbuvir will significantly reduce

Source: http://www.makemedicinesaffordable.org The Ministry of Economic Development and Trade of Ukraine (MEDT) refused to grant the pharmaceutical company Gilead a patent for hepatitis C drug sofosbuvir.  On 2 March 2018, the MEDT issued the order (No. 305) which approved the … Continue reading

Posted in Hepatitis C, Sofosbuvir, Uncategorized | Leave a comment

18 hospitals offer free DAA therapy for treatment of Hepatitis C

KUALA LUMPUR: Eighteen selected hospitals across the country have begun offering free Sofosbuvir-based direct-acting antiviral (DAA) therapy for treatment of Hepatitis C since early this month, according to Health Minister Datuk Seri Dr S. Subramaniam. He said the first phase … Continue reading

Posted in Hepatitis C, Uncategorized | Leave a comment

PhRMA is angered by Colombia’s move to cut prices for hepatitis C drugs

By Ed Silverman, StatNews In the latest battle between drug makers and the Colombian government,  an industry trade group has asked the Colombian health minister to scrap a move that is designed to unilaterally lower the prices of hepatitis C drugs or, eventually, issue compulsory licenses. … Continue reading

Posted in Compulsory Licensing, Drug prices, Hepatitis C, Uncategorized | Leave a comment

UACT statement regarding Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs

January 8, 2018 New Delhi Source: U Act UACT applauds the Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. … Continue reading

Posted in Compulsory Licensing, Hepatitis C | Leave a comment